Multimodal therapy for hepatocellular carcinoma:

A complementary approach to liver transplantation 

Autores: Schumacher P Andrew, Powell James J, MacNeill Andrea J, Buczkowski Andrzej K, Erb Siegfried R, Ho Stephen G, Scudamore Charles H, et al

Resumen

Objective: To evaluate the survival benefit of multimodal therapy for the treatment of HCC. Background: Orthotopic liver transplantation (OLT) is considered the treatment of choice for selected patients with hepatocellular carcinoma (HCC). However, donor organ shortages and patients whose HCCs exceed OLT criteria require consideration of alternate therapeutic options such as hepatic resection, radiofrequency ablation (RFA), ethanol injection (EI), transarterial chemoembolization (TACE), and chemotherapy (CTX). This study was performed to evaluate the survival benefit of multimodal therapy for treatment of HCC as complementary therapy to OLT. Methods: A retrospective review was conducted of HCC patients undergoing therapy following multidisciplinary review at our institution fron 1996-2006 with a minimum of a 2 year patient follow-up. Data were available on 247/252 patients evaluated. Relevant factors at time of diagnosis included symptoms, hepatitis B (HBV) and C (HCV) status, antiviral therapy, Child-Pugh classification, portal vein patency, and TNM staging. Patients underwent primary treatment by hepatic resection, RFA, EI, TACE, CTX, or were observed (best medical management). Patients with persistent or recurrent disease following initial therapy were assessed for salvage therapy. Survival curves and pairwise multiple comparisons were calculated using standard statistical methods. Results: Mean overall survival was 76.8 months. Pairwise comparisons revealed significant mean survival benefits with hepatic resection (93.2 months), RFA (66.2 months), and EI (81.1 months), compared with TACE (47.4 months), CTX (24.9 months), or observation (31.4 months). Shorter survival was associated with symptoms, portal vein thrombus, or Child-Pugh class B or C. HCV infection was associated with significantly shorter survival compared with HBV infection. Antiviral therapy was associated with significantly improved survival in chronic HBV and HCV patients only with earlier stage disease. Conclusion: Multimodal therapy is effective therapy for HCC and may be used as complementary treatment to OLT.

Palabras clave: Liver resection radiofrequency ablation chemoembolization liver transplantation.

2010-05-11   |   747 visitas   |   Evalua este artículo 0 valoraciones

Vol. 9 Núm.1. Enero-Marzo 2010 Pags. 23-32 Ann Hepatol 2010; 9(1)